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Abstract 
The discovery of a new antitrypanosomal hit compound that cures an acute (STIB 900) 
mouse model of Trypanosoma brucei rhodesiense trypanosomiasis is described. This 
bis(2-aminoimidazolinium) dicationic compound proved to be an excellent DNA minor 
groove binder suggesting a possible mechanism for its trypanocidal activity. From these 
studies, the 4,4’-diaminodiphenylamine skeleton emerged as a good scaffold for 
antitrypanosomal drugs.  
   
Introduction 
Human African trypanosomiasis, HAT, caused by sub-species of the parasitic 
protozoan Trypanosoma brucei, is a daily threat to millions of people in sub-Saharan 
Africa and represents a great human and social cost in affected areas.
1
 However, it is 
one of the most neglected disease in the world and no currently available drug to treat 
this condition is satisfactory (high cost, unacceptable side-effects, intravenous mode of 
administration and drug resistance are all issues restricting use).
2
 The arsenic-based 
drug melarsoprol, which is the only medicine available to treat the CNS stage of the 
disease caused by T. b. rhodesiense and is still the principal drug used for late stage 
disease, is highly toxic.  Treatment failures with melarsoprol are reaching up to 30% in 
some foci.
3
 With no new drugs to treat late stage disease in the pipeline the prospect of 
being unable to treat sleeping sickness has emerged as an alarming threat. Hence, the 
discovery of new lead compounds that kill trypanosomes, but also which penetrate into 
the CNS and cure the second stage HAT is a priority in international health.
4
 
We previously reported aromatic and aliphatic families of bisguanidine and bis(2-
aminoimidazoline) derivatives structurally related to pentamidine and synthalin with a 
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great  potential as antitrypanosomal agents.
5
 Some of these compounds (Figure 1) 
showed excellent activity and selectivity (> 3000 for 2a) towards the parasite in vitro, 
making them promising new trypanocidal hit compounds. Since pentamidine (Figure 2) 
is only effective in the treatment of first stage T. b. gambiense sleeping sickness (the 
chronic form of the disease), new safe compounds active against the acute and the 
chronic CNS stage are of particular interest. Encouraged by the excellent in vitro 
activity displayed by some compounds, we selected a series of diphenyl (1–5) and 
aliphatic (6–9) derivatives for in vivo testing in two acute mouse models (STIB 795 and 
STIB 900). The STIB 795 model has proven relatively easy to cure. STIB 900 on the 
other hand has proven relatively difficult to cure. For example, pentamidine and 
diminazene cure the STIB 795 model but not the STIB 900 model, possibly because in 
this latter model the parasites invade extravascular sites early in infection.  The most 
active compound, 2a, which was able to cure 100% of the mice in these models was 
also evaluated in the second stage CNS mouse model (GVR 35 strain) a model which is 
cured only by a minority of trypanocides which are able to cross the blood–brain barrier 
(BBB).  
Many agents of the aromatic diamidine
6
 or diguanidine class have strong binding 
affinity for the DNA at AT-rich sites.
7
 Some evidence suggests that this interaction may 
contribute to the antiprotozoal activity frequently associated with this class of 
compound.  Transcription and activity of other DNA-dependent enzymes may all be 
inhibited by dicationic drugs.
8
 In order to gain insight into the mechanism of action of a 
series of dicationic compounds that we have shown to have profound trypanocidal 
activity, the DNA binding affinity (i.e., ∆Tm values) of the diphenyl (1–5) and aliphatic 
(6–9) derivatives was measured.
9
 
 
 4 
X
R R
N
H
NH2
N
H
H2N
NH2
N
H
HN
NH
N
H
OEt
EtO
P
C5H11
C5H11
C5H11
a b c
f
BocHN
NBoc
N
H
e
BocN
NBoc
N
H
d
R
     X
1: CH2
2: NH
3: CO
4: SO2
5: 1,4-piperazine
6: -(CH2)6-
7: -(CH2)8-
8: -(CH2)9-
9: -(CH2)12-
X R
R
 
Figure 1. Bisguanidine and bis(2-aminoimidazoline) diphenyl and aliphatic derivatives 
with activity and selectivity against T. brucei rhodesiense. 
 
Another factor that is essential to the efficacy and selectivity of antitrypanosomal 
drugs is their effective uptake by the parasite. Dicationic drugs have very slow rates of 
diffusion across biological membranes and their uptake is dependent on different 
transporters.
10
 Three different transporters have been implicated in the transport of 
pentamidine: the high and low affinity pentamidine transporters (HAPT and LAPT, 
respectively whose endogenous substrates are not known) and the P2 aminopurine 
transporter.
11
 The P2 transporter also participates in the uptake of other diamidines (e.g. 
diminazene, propamidine) and the melaminophenyl arsenicals (e.g. melarsoprol) that 
bear the common recognition motifs (i.e. amidine moiety, aromatic ring and 
electronegative heteroatom, Figure 2).
12–14
 Diphenyl bisguanidines too carry this P2 
recognition motif.  The loss of the P2 transporter alone appears to be sufficient to render 
trypanosomes highly resistant to some drugs, for example diminazene.
15
 The loss of the 
transporter also correlates with resistance to melarsoprol, although in this instance 
additional transporters too must be lost in order to achieve high level resistance.
16
  A 
number of other melamine-based
17
 and benzamidine based
18
 compounds designed for 
entry via the P2 transporter also appear to have additional routes into the cell. With 
regard to understanding about the likelihood of resistance arising to compounds that 
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appear to be substrates for the P2 transporter, it is of importance to know whether 
uptake is exclusively via this transporter or whether alternative routes into the cell also 
exist. Thus the most active compounds, 2a and 2b, were also evaluated against a cell 
line defective in P2 mediated transport to gain information about their possible 
mechanism of uptake.  
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Figure 2. Structure of antitrypanosomal drugs that bear the P2 transporter recognition 
motifs.  
 
Results and discussion 
DNA binding affinity at AT-rich sites. Table 1 presents the results of DNA binding 
as estimated by ∆Tm measurements (i.e., the difference between the Tm of DNA and the 
Tm observed in the presence of drug
9
) with a non-alternating AT sequence DNA 
polymer.  In general, the diphenyl dicationic derivatives showed a strong DNA binding 
with ∆Tm values in the range of pentamidine for unsubstituted guanidines and 2-
aminoimidazolines (1a, 1b, 2a, 2b, 3b, 5a and 5b) whereas substituted guanidines 1c 
and 2c had lower values. Differences in binding affinity were observed depending on 
the bridge linking both phenyl rings: compound 2, with a NH bridge, had higher ∆Tm 
value than 1 (CH2 bridge) and 4 (SO2 bridge). This result could be explained by a better 
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fit of 2 to the minor groove in contrast to 1 and 4 the dihedral angle of which would not 
be expected to fit the width of the groove. By contrast, compound 3b (CO bridge) 
bound strongly (27.6 ºC) as expected based on a better fit to the groove. In those series, 
a good correlation was observed between in vitro activity and DNA binding affinity for 
the 2-aminoimidazoline compounds (2a > 1a >> 4a) whereas a rough correlation was 
observed for the guanidine analogues (2b > 3b ~ 1b >> 4b). Indeed, the best 
trypanocides in vitro, 2a and 2b, were also the best DNA binders of the series (38.5 and 
29.6 ºC, respectively).  
Moreover, plotting Tm versus IC50 values against trypanosomes did reveal the two to 
be correlated for two sets of compounds as shown in Figure 3. Compounds 4a and 4b 
were omitted because they showed no activity which might conceivably relate to their 
inability to enter cells. Further experiments would be required to test this. In addition, 
the alkyl dicationic derivatives (6a, 6b–9b) were omitted because there was no 
correlation between activity and Tm increase.  It is likely that there are multiple modes 
of activity for dications, each of which contributes to the overall IC50.  In the case of the 
alkyl group sets an alternative mode of action might mask activity that results from 
DNA binding. 
The nature of the cationic moiety appeared to play a role in the DNA binding affinity 
of these diphenyl compounds. Compounds with 2-aminoimidazolinium cations had 
stronger binding than their guanidinium counterparts (compare 1a/1b, 2a/2b and 5a/5b) 
and two molecules (2a and 5a) bound to DNA with higher affinity than pentamidine. 
The more bulky and flexible bis(n-pentylphosphonium) derivative 3f had negligible 
DNA binding in contrast to its guanidine counterpart. Interestingly, derivatives 5a with 
2-aminoimidazolinium cation bind more strongly than its amidine counterpart (N,N’-
bis(4-amidinophenyl)piperazine, Figure 2) described by Donkor et al.
19
 This could 
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relate to the higher basicity of this cation compared to the amidinium or the capacity to 
form hydrogen bonds. As expected, based on the greater negative potential at the floor 
of the minor groove in AT rich regions,
20
 the uncharged Boc-protected analogue (5e) 
had insignificant binding. A good correlation between DNA binding affinity and 
trypanocidal activity was observed with those derivatives (5a> 5b >> 5e) which 
confirmed the findings of Donkor et al. for this family of conformationally restricted 
pentamidine congeners.
19
  
Hence, the mechanism of action of the diphenyl compounds which have strong DNA 
interaction could be due in part to the formation of a DNA complex. 
On the other hand, the alkyl dicationic compounds had much lower affinity than 
pentamidine, in the range 9.1–14 ºC. This is probably because these derivatives lack the 
aromatic rings that help to position the cations to interact with A and T bases at the floor 
of the minor groove. Despite of the low DNA binding, some of these aliphatic 
molecules (7b, 8b and 9b) showed excellent antitrypanosomal activity in vitro. This 
could indicate mechanisms of action other than binding to DNA, although it is also 
noteworthy that dications, including pentamidine and diminazene accumulate to very 
high levels within trypanosomes, with the mitochondrion in particular concentrating the 
drug. Thus, even low affinity binding may lead to high overall interactions with 
kinetoplast DNA at these greatly elevated concentrations.   
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Figure 3. Plot of log (1/IC50) vs Tm for the diphenyl series showing a good correlation 
between in vitro antitrypanosomal activity and Tm increase for two sets of compounds: 
■ (1b, 1c, 2b, 2c and 3f) and ● (1a, 2a, 3b, 5a, 5b and 5e).  
 
In vivo activity. The eight compounds displaying the best in vitro activities and 
selectivity were then administered intraperitoneally to infected mice to determine 
whether activity was retained in vivo (Table 2). Two diphenyl compounds (2a and 2b) 
cured all mice infected with T. b. brucei STIB 795 at 20 mg/kg. The Boc-protected 
analogue 2d had little effect on survival (10.25 days) and the 1,4-piperazine compound 
5a was toxic after the first treatment at 20 mg/kg. The four alkyl derivatives tested did 
not result in cures. Two of them (9a and 9b) were toxic at 20 mg/kg, whereas the other 
two only extended the survival rate at 10 mg/kg (> 37.5 and 13.5 days, respectively).  
This first screening against the acute STIB 795 model revealed that the most 
promising compounds were the 2-aminoimidazoline (2a) and guanidine (2b) diphenyl 
analogues with a NH bridge. Hence, these compounds were tested by i.p. administration 
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in the difficult T. b. rhodesiense STIB 900 mouse model. At 20 mg/kg, the guanidine 
derivative 2b cured 2/4 mice whereas 2a cured 4/4 mice. Lower doses of 2a (5 and 10 
mg/kg) achieved only 1/4 cure. On the basis of these excellent in vivo results, 2a was 
assayed in the chronic CNS mouse model (GVR 35) of sleeping sickness. 
Unfortunately, no cures were obtained, probably due to a poor BBB penetration of this 
hit compound. Indeed, this kind of guanidine-like compound has very basic nitrogen 
atoms that are charged at physiological pH and thus potentially poorly liposoluble and 
not able to cross the BBB by passive diffusion. Different synthetic strategies exist to 
improve the pharmacokinetics of cationic compounds such as amidines
21
 or 
guanidines.
22
 These pro-drug approaches are currently being studied in our laboratory.  
 
 
Roles for the P2 transporter in uptake and resistance.  Since these compounds 
carry a motif typical of substrates of the P2 aminopurine transporter, and that loss of 
this transporter can contribute to the development of resistance to drugs that enter via 
this route, we evaluated the in vitro activity of 2a and 2b against both the wild type and 
the TbAT1 knockout line that lacks the P2 transporter.
16
 The difference in activity 
between the two lines for both compounds was small or insignificant (Table 3).  This is 
similar to results obtained with pentamidine, known to enter via other transporters,
11
 but 
different from diminazene which enters predominantly via the P2 transporter.
15
 It has 
recently been shown that a number of other melamine based
17
  and benzamidine-based
18
  
trypanocides also enter via other transporters in addition to P2.  This is significant as it 
indicates that parasites selected for resistance to drugs through loss of the P2 transporter 
alone, will not show cross–resistance to these compounds.   
 
Conclusion 
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We have described a correlation between the DNA binding affinity and trypanocidal 
activity of two series of diphenyl dicationic derivatives previously found by screening 
of our in-house library.
5
 Two hit compounds (2a and 2b), which demonstrated excellent 
DNA binding affinity and in vivo activity in two models (STIB 795 and STIB 900) of 
acute T. brucei infections in mice, emerged from this study. The bis(2-
aminoimidazolinium) compound 2a was particularly active and upon i.p. injection of 20 
mg/kg/day for 4 days, cured 100% of treated mice in the difficult to cure T. b. 
rhodesiense STIB 900 model, without overt toxicity. Although this compound could not 
cure the rodent model of CNS infection, probably due to poor BBB penetration, it has 
potential to be modified (e.g. using a pro-drug approach) in order to improve its CNS 
delivery. Hence, the 4,4’-diphenylamine scaffold, and 2a in particular, represents a 
promising dicationic hit compound for the treatment of sleeping sickness. 
In this series of bis(2-aminoimidazolinium) diphenyl derivatives, a good correlation 
between in vitro antitrypanosomal activity and DNA binding was observed, suggesting 
that this binding could be part of their mechanism of action. Finally, we showed that 
even though the P2-aminopurine transporter may be involved in the uptake of these hit 
compounds, this was not the sole route of entry of these guanidine-like compounds into 
trypanosomes and thus parasites that have lost the P2 transporter in selection of 
resistance to other drugs will not be cross-resistant to these compounds. 
 
Experimental Section 
DNA binding assays. Poly(dA)·poly(dT) was obtained from Pharmacia Corp. and 
characterized as previously described.
9
 Thermal melting experiments were conducted 
with Cary 300 spectrophotometers interfaced to microcomputers as previously 
described.
9
 A thermistor fixed into a reference cuvette was used to monitor the cell 
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temperature. A 1 mL sample of poly(dA)·poly(dT) DNA in buffer (MES buffer 
contained 0.01 M MES and 10
-3 
M EDTA with the pH adjusted to 6.2 with NaOH) was 
placed in a 1 cm path length reduced volume quartz cell, and the concentration checked 
by measuring the absorbance at 260 nm. Experiments were conducted at a concentration 
of 50 µM DNA bases and Tm values were determined from first derivative plots. The 
free polydA·polydT duplex had a Tm of 46 °C. Compounds were compared by the 
increase in Tm [Tm(complex) - Tm(free DNA)] they produced at a molar ratio of 0.3, 
compound to nucleic acid bases (saturating amounts of the compound). Ratios greater 
than 0.3 did not affect the Tm values.  The estimated errors in the ∆Tm values are 0.5 
°C.   
In vitro activity against T. brucei spp. IC50 determinations for T. b. rhodesiense 
STIB 900 were done using the Alamar blue assay.
5,23
 Bloodstream form T. brucei 
brucei (strain 427) were cultivated in HMI-9 medium containing 20% foetal calf serum 
at 37 
o
C in a humidified CO2 environment. To investigate whether transport of these 
compounds through the P2 transporter is necessary for activity, compounds were 
assayed against the T. brucei brucei trypomastigotes, either wild type or P2 knockout 
mutants (TbAT1
-/-
).
16
 The Alamar Blue assay
23
  was used to determine IC50 values 
against wild-type lines and the TbAT1
-/-
 derivative. 
 
In vivo activity against T. brucei. Female NMRI mice weighting 22–25 g were 
infected with cryopreserved stabilates of T. brucei brucei STIB 795 (derivate of strain 
427) or T. brucei rhodesiense STIB 900. Each mouse was infected intraperitoneally 
with 1×10
5
 (STIB 795) or 2 × 10
4
 (STIB 900) bloodstream forms. Groups of four mice 
were treated intraperitoneally with the compounds on days 3, 4, 5, and 6. A control 
group remained untreated. The parasitemia of all animals was checked every second day 
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up to day 14 post-infection and two times a week thereafter until 60 days. Death of 
animals was recorded to calculate the mean survival time. Surviving and aparasitemic 
mice were considered cured at 60 days and then euthanized. 
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Table 1. DNA Binding Affinity and in Vitro Trypanocidal Activity of Diphenyl and 
Aliphatic Derivatives 
Structure Compound X 
T. b. rhodesiense 
STIB 900 
IC50 (nM)
a
 
∆Tm (ºC) b 
poly(dA.dT)2 
Pentamidine -O(CH2)5O- 2.2 32.3 
N,N’-bis(4-amidinophenyl)piperazine N N
 
13.5
c
 
19.4 
 
1a  897 18.8 
 
1b CH2 161 15.0 
 
1c  316 5.3 
 
2a  69 38.5 
 
2b NH 22 29.6 
2c  228 13.6 
3a  2050 nd 
X
R R
 
3b CO 206 27.6 
 
3f  414 1.2 
 
4a SO2 32 x 10
3
 12.1 
 
4b  4.3 x 10
3
 12.8 
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5a  118 38.8 
 
5b N N
 
270 27.8 
 
5e  13.8 x 10
3 
0.2 
 
6a -(CH2)6- 19.3 × 10
3
 14.0 
 
6b  8.05 × 10
3
 13.1 
R X R
 
7b -(CH2)8- 251 13.1 
 
8b -(CH2)9- 49 12.2 
 
9b -(CH2)12- 47 9.1 
a
 Average of duplicate determinations [values taken from ref.
 
5]; 
b
 Buffer: MES (0.01 
M) + EDTA (0.001M). Ratio compound/DNA is 0.3; See ref. 9; 
c
 Value for drug-
resistant clinical isolate of T. b. rhodesiense KETRI 243 (taken from ref. 19). 
a
HN
N
HNH  b
NH2
NH2N
H  c
NH2
N
HNH
EtO
OEt
  e
NBoc
NHBocN
H  f
P
C5H11
C5H11
C5H11
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Table 2. In Vivo Antitrypanosomal Activities for Diphenyl and Aliphatic Derivatives in 
the Acute (STIB 795 and STIB 900) and Late stage (GVR 35) Mouse Models. 
a
 See experimental section for details of STIB 795 (T. b. brucei) and STIB 900 (T. b. 
rhodesiense) models. For GVR 35, see ref. 24. 
b
 ip = intraperitoneal. 
c
 Number of mice 
that survive and are parasite free for 60 days. 
d
 Average days of survival. 
e
 All mice died 
after the first treatment. 
f
 All mice died after the third treatment.  
 
Compound Mouse 
model
a
 
Dosage 
route
b
 
Dosage 
(mg/kg) 
Cured
c
/Infected Survival  
(days)
d
 
Control STIB 795 - - 0/4 6.25 
Control STIB 900 - - 0/4 7.5 
Control GVR 35 - - 0/5 38  
Diminazene 
diaceturate 
GVR 35 ip 1×40 0/5 71 
2a STIB 795 ip 4 × 20  4/4 >60 
2a STIB 900 ip 4 × 20 4/4 > 60 
2a STIB 900 ip 4 × 10 1/4 > 40 
2a STIB 900 ip 4 × 5 1/4 > 42.5 
2a GVR 35 ip 5 × 20 0/5 40.8
 
2b STIB 795 ip 4 × 20 4/4 > 60 
2b STIB 900 ip 4 × 20 2/4 > 43.3 
2d STIB 795 ip 4 × 20 0/4 10.25 
5a STIB 795 ip 4 × 20 toxic -
e
 
7b STIB 795 ip 4 × 10 0/4 > 37.5 
8a STIB 795 ip 4 × 10 0/4 13.5 
9a STIB 795 ip 4 × 20 toxic -
 f
 
9b STIB 795 ip 4 × 20 toxic -
 f
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Table 3. In Vitro Activities against Bloodstream T. brucei.  
IC50 (nM) 
Compound T. brucei brucei 
AT1 wild type 
T. brucei brucei 
AT1 knockout
a
 
2a 63.7 162 
2b 3.0 2.2 
Pentamidine* 11 26 
Diminazene* 301 5,773 
a 
Mutant with a non functional P2 transporter. 
* data taken from reference 16  
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